Acute cardiac care & resuscitationCohort study
Generalizability of Landmark Temporary MCS Device Trials
- retrospective analysis
Authors' conclusion
Patients meeting the landmark CS trial criteria represent a small, high-risk subset of the real-world CS population, highlighting a substantial evidence gap for the majority of CS patients receiving tMCS in clinical practice. Enhancing registry enrollment of specific CS subsets and adopting innovative analytic strategies could bridge gaps between randomized controlled trials findings and real-world applicability.
Study context
- Population
- Cardiogenic shock (CS) patients enrolled between 2020 and 2024 in the CS Working Group registry
- Exposure
- baseline characteristics and usage patterns of temporary mechanical circulatory support (tMCS) devices among trial-eligible and trial-ineligible patients
Main finding
As reported in the abstract
DanGer Shock
19.3%
IABP-SHOCK II
28.4%
ECLS-SHOCK
23.6%
Observational data: associations, not effects.
Further findings
Most restrictive criteria
- Hypotension and elevated lactate thresholds were the most restrictive criteria across trials
CS severity and end-organ damage
- Trial-eligible patients had more severe CS and end-organ damage than ineligible patients
Actual device use
- DanGer-like patients receiving Impella CP as their first device
- 20%
- Actual device use in real-world practice differed markedly from trial assignments
Original publication
Summarised from the published abstract; every number is checked against it